用户名/邮箱
登录密码
验证码
看不清?换一张
您好,欢迎访问! [ 登录 | 注册 ]
您的位置:首页 - 最新资讯
European Commission authorizes GSK's HIV prevention drug
2023-09-20 00:00:00.0     福克斯新闻-世界     原网页

       close

       Video

       Fox News Flash top headlines for September 19 Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com.

       The European Commission has authorized GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.

       EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT

       Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.

       The GlaxoSmithKline logo is seen in this illustration, Aug. 10, 2022. (REUTERS/Dado Ruvic/Illustration/File Photo)

       Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.

       CLICK HERE TO GET THE FOX NEWS APP

       


标签:综合
关键词: COMMISSION     EUROPEAN     Illustration     Fox News     Healthcare's cabotegravir     HIV-focused     top headlines    
滚动新闻